Loading people...
Cory Freedland invests in early-stage biotechnology companies, specifically those developing novel therapeutics, innovative platform technologies, and disruptive medical devices across various disease areas. His focus is on solutions addressing unmet medical needs.
Cory Freedland works as a Principal at Samsara BioCapital, a prominent life sciences venture capital firm.
Cory Freedland stands as a pivotal Principal at Samsara BioCapital, a distinguished life sciences venture capital firm renowned for its strategic investments in groundbreaking biotechnology companies. In his role, Mr. Freedland is instrumental in shaping the future of medicine by identifying, evaluating, and nurturing early-stage ventures poised to deliver transformative therapeutic solutions. His work at Samsara BioCapital underscores a deep commitment to advancing scientific innovation from concept to clinical reality.
At Samsara BioCapital, Cory Freedland's investment focus spans a broad spectrum of the life sciences sector. He is particularly dedicated to companies developing novel therapeutics, innovative platform technologies, and disruptive medical devices that address significant unmet medical needs. His expertise allows him to delve into complex scientific data and market dynamics, ensuring that Samsara BioCapital invests in opportunities with the highest potential for both scientific breakthrough and patient impact. He actively supports portfolio companies, leveraging his extensive industry knowledge to guide their strategic development and operational growth.
Before joining Samsara BioCapital, Mr. Freedland honed his financial and strategic acumen through diverse experiences within the healthcare and investment sectors. He previously served as an Associate at Third Rock Ventures, another highly respected life sciences venture capital firm, where he gained invaluable insights into company creation and early-stage investment strategies. Prior to his venture capital career, Cory worked as an Analyst in the Healthcare Investment Banking division at Goldman Sachs. This foundational experience provided him with a robust understanding of corporate finance, mergers and acquisitions, and capital markets within the healthcare industry.
Cory Freedland's academic background further solidifies his expertise. He graduated from Harvard University with an AB in Chemistry and Physics, providing him with a strong scientific foundation that is crucial for evaluating complex biotechnological innovations. This blend of scientific rigor and financial expertise positions him as a highly effective investor capable of discerning promising technologies and guiding them towards success. His contributions are vital in Samsara BioCapital's mission to back visionary entrepreneurs and scientists who are developing the next generation of life-saving medicines.
Cory Freedland is a Principal at Samsara BioCapital, a biotechnology-focused venture capital firm based in Palo Alto, California. He holds a PhD in Pharmacology from the Wake Forest University School of Medicine and an MBA from the UC Berkeley Haas School of Business. Prior to his current investment role, Freedland worked in corporate business development at Roche Partnering and gained early venture capital experience at Presidio Partners. His professional expertise spans the life sciences sector, with a specific emphasis on early-stage therapeutic companies, neuroscience, and medical device investments. While public deal flow data indicates he has completed zero deals as a lead investor, he actively helps manage the broader investment portfolio for the Samsara BioCapital fund. Freedland currently focuses on leveraging his academic pharmacology background and corporate pharmaceutical experience to evaluate emerging biotechnology ventures.
